According to the most recent analysis by Emergen Research, the market for duchenne muscular dystrophy in the world reached $1.03 billion in 2021 and is projected to grow at a rate of 40.7% over the forecast period. The prevalence of duchenne muscular dystrophy is rising, and there are more clinical trials and studies being conducted in the area of duchenne muscular dystrophy-based treatments, which are key contributors in the market's expansion. Additionally, the market for drugs to treat Duchenne muscular dystrophy has shown tremendous revenue increase in recent years due to the quick development of these drugs in clinical trials.
The report examines the market in terms of importance, share, size, demand and supply, patterns, competitive landscape, industrial chain analysis, and other important factors. The report also provides a detailed outlook for the industry's driving and restraining forces, as well as micro and macroeconomic factors that are expected to influence its development.
The study outlines the rapidly evolving and growing market segments along with valuable insights into each element of the industry. The industry has witnessed the entry of several new players, and the report aims to deliver insightful information about their transition and growth in the market. Mergers, acquisitions, partnerships, agreements, product launches, and joint ventures are all outlined in the report.
The leading market contenders listed in the report are:
PTC Therapeutics, Eli Lilly and Company, Sarepta Therapeutics, Bristol-Myers Squibb Company, Nippon Shinyaku, Acceleron Pharma Inc., BioMarin Pharmaceutical, Inc., Pfizer, Ltd., Tahio Pharmaceutical Co. Ltd., and Lexicon Pharmaceuticals, Inc.
Research Report on the Duchenne Muscular Dystrophy Market Addresses the Following Key Questions:
Who are the dominant players of the Duchenne Muscular Dystrophy market?
Which regional market is anticipated to have a high growth rate over the projected period?
What consumer trends and demands are expected to influence the operations of the market players in the Duchenne Muscular Dystrophy market?
What are the key growth drivers and restraining factors of the Duchenne Muscular Dystrophy market?
What are the expansion plans and strategic investment plans undertaken by the players to gain a robust footing in the market?
What is the overall impact of the COVID-19 pandemic on the Duchenne Muscular Dystrophy market and its key segments?
Emergen Research has segmented the global Duchenne Muscular Dystrophy market on the basis of type, type of care, and region
Segments Covered in this report are:
Treatment Type Outlook (Revenue, USD Million; 2019-2030)
Corticosteroid therapy
Exon-Skipping Therapy
Mutation Suppression
Gene Therapy
End-Use Outlook (Revenue, USD Million; 2019-2030)
Hospitals & Clinics
Home-Care
Others
Regional Outlook (Revenue, USD Million; 2019-2030)
North America
U.S.
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Benelux
Rest of Europe
Asia Pacific
China
India
Japan
South Korea
Rest of APAC
Latin America
Brazil
Rest of LATAM
Middle East & Africa
Saudi Arabia
UAE
South Africa
Turkey
Rest of MEA
In conclusion, the Duchenne Muscular Dystrophy Market report is an exhaustive database that will help readers formulate lucrative strategies. The Duchenne Muscular Dystrophy Market report studies the latest economic scenario with value, drivers, constraints, growth opportunities, challenges, demand and supply ratio, production capacity, import/export status, growth rate, and others. Additionally, the report also undertakes SWOT Analysis and Porter’s Five Forces Analysis to study the leading companies.